BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tvedt THA, Steien E, Øvrebø B, Haaverstad R, Hobbs W, Wardęcki M, Tjønnfjord GE, Berentsen SA. Sutimlimab, an investigational C1s inhibitor, effectively prevents exacerbation of hemolytic anemia in a patient with cold agglutinin disease undergoing major surgery. Am J Hematol 2022;97:E51-4. [PMID: 34778998 DOI: 10.1002/ajh.26409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Berentsen S, Barcellini W, D'Sa S, Jilma B. Sutimlimab for treatment of cold agglutinin disease: why, how and for whom? Immunotherapy 2022. [PMID: 35946351 DOI: 10.2217/imt-2022-0085] [Reference Citation Analysis]
2 Chen Y, Chu JMT, Chang RCC, Wong GTC. The Complement System in the Central Nervous System: From Neurodevelopment to Neurodegeneration. Biomolecules 2022;12:337. [PMID: 35204837 DOI: 10.3390/biom12020337] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]